Page last updated: 2024-09-05

enzastaurin and Lymphoma

enzastaurin has been researched along with Lymphoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Almasan, A; Bodo, J; Hsi, ED; Maciejewski, JP; Sedlak, J1
Ogura, M1

Trials

1 trial(s) available for enzastaurin and Lymphoma

ArticleYear
[Current development of new drugs in malignant lymphoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat

2012

Other Studies

1 other study(ies) available for enzastaurin and Lymphoma

ArticleYear
HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
    Apoptosis : an international journal on programmed cell death, 2011, Volume: 16, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lymphoma; Sulfides; Tumor Suppressor Protein p53; Valproic Acid; Vorinostat

2011